cefalexin sandoz
sandoz new zealand limited - cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage); - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage) excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.
cefalexin sandoz
sandoz new zealand limited - cefalexin monohydrate 55.206 mg/ml equivalent to cephalexin 50 mg/ml (+5% stability overage); - granules for oral suspension - 250 mg/5ml - active: cefalexin monohydrate 55.206 mg/ml equivalent to cephalexin 50 mg/ml (+5% stability overage) excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.
cefalexin sandoz cefalexin monohydrate 250 mg capsules blister pack
sandoz pty ltd - cefalexin -
cefalexin sandoz
sandoz new zealand limited - cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg; - capsule - 500 mg - active: cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg excipient: gelatin magnesium stearate microcrystalline cellulose titanium dioxide water
cefalexin (flynn)
max health limited - cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml; - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.
cefalexin (flynn)
max health limited - cefalexin monohydrate 52.591 mg/ml equivalent to cefalexin 50mg/ml; - granules for oral suspension - 250 mg/5ml - active: cefalexin monohydrate 52.591 mg/ml equivalent to cefalexin 50mg/ml excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.
cefalexin 500mg tablets
teva uk ltd - cefalexin - oral tablet - 500mg
cefalexin 500mg tablets
a a h pharmaceuticals ltd - cefalexin - oral tablet - 500mg
cefalexin 500mg tablets
actavis uk ltd - cefalexin - oral tablet - 500mg
cefalexin 500mg tablets
viatris uk healthcare ltd - cefalexin - oral tablet - 500mg